Endothel Pharma ApS: Financial statements 2022
CVR: 37988936
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Endothel Pharma ApS (CVR 37988936) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -47,868 and a net result of DKK -76,253 compared with DKK -46,607 the year before. Equity in the 2022 report amounted to DKK -203,322.
- Gross Profit
- DKK -47,868
- Profit/Loss
- DKK -76,253
- Equity
- DKK -203,322
- Total Assets
- DKK 554,669
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -48 t. | -76 t. | -203 t. | 0 |
| 2021 | - | -25 t. | -47 t. | -127 t. | 0 |
| 2020 | - | -13 t. | -29 t. | -80 t. | 0 |
| 2019 | - | -23 t. | -36 t. | -52 t. | - |
| 2018 | - | -53 t. | -59 t. | -40 t. | 0 |
Official annual report
Keep an eye on Endothel Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Endothel Pharma ApS has published its annual report for 2021. Gross profit came to DKK -25,128, and the net result was DKK -46,607.
About Endothel Pharma ApS
Endothel Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Rikke Stine Friis Fléron. The company is owned by Bo Jesper Hansen, Pär Ingemar Johansson and Trial-Lab Holding AB. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -43,536 and a net result of DKK -87,006 compared with DKK -81,618 the year before. Equity in the 2025 report amounted to DKK -462,946.